Amarin (AMRN) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amarin (AMRN) has outperformed Upstream Bio (UPB) over the past year, losing 37.6% versus a loss of 75.3%. Amarin is the larger company by market cap ($253.9 million vs $252.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | UPB |
|---|---|---|
| Share price | $12.02 | $4.61 |
| Market cap | $253.90M | $252.49M |
| 1-day change | -0.41% | +0.44% |
| YTD return | -13.90% | -83.02% |
| 1-year return | -37.62% | -75.31% |
| 5-year return | -88.35% | — |
| Forward P/E | 12.27 | — |
| EPS (TTM) | $-1.20 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.90 | $33.68 |
| 52-week low | $11.83 | $4.50 |
| Distance from 52-week high | -42.49% | -86.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +3.99% | +575.49% |
| Average volume | 66.16K | 610.08K |
| Shares outstanding | 21.12M | 54.77M |
| Employees | 80 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRN has outperformed UPB by 37.7 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
AMRN vs UPB FAQ
Which is bigger, Amarin or Upstream Bio?
Amarin (AMRN) is larger, with a market capitalization of $253.90M compared with $252.49M for Upstream Bio (UPB).
Which stock has performed better over the past year, AMRN or UPB?
AMRN returned -37.62% over the past 12 months, compared with -75.31% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.